Comparison of Pharmacokinetics and Pharmacogenetics of Once- and Twice-Daily Tacrolimus in the Early Stage After Renal Transplantation
Comparison of Pharmacokinetics and Pharmacogenetics of Once- and Twice-Daily Tacrolimus in the Early Stage After Renal Transplantation
复制标题
DOI：
10.1097/tp.0b013e31826bc400
复制
发表时间：
2012-11-27
期刊：
影响因子：
6.2
通讯作者：
Miura, Masatomo
中科院分区：
文献类型：
--
作者：
Niioka, Takenori;Satoh, Shigeru;Miura, Masatomo
背景资料。这项研究考察了每日一次释放他克莫司改良制剂(Tac-QD)和需要每日两次摄入的原始制剂(Tac-Bid)在新肾移植患者中的药代动力学和药物遗传学差异。47例患者分别接受TAC-QD和TAC-QD治疗。于移植后第28天对各制剂的药代动力学及细胞色素P450 3A5 6986A>；G和ABCB1 3435C>；T进行药物遗传学分析。他克莫司的剂量调整谷水平(C-0)和浓度-时间曲线下面积(AUC(0-24))在Tac-Qd组比Tac-Bid组低约25%。Tac-Bid组和Tac-Qd组的AUC(0.575~24)与C-0之间有良好的相关性(r(2)=0.99，P<0.05)。
Background. This study investigated pharmacokinetic and pharmacogenetic differences between a modified-release once-daily formulation of tacrolimus (Tac-QD) and the original formulation requiring twice-daily intake (Tac-BID) in de novo renal transplant recipients.Methods. Forty-seven and 25 patients who received Tac-BID and Tac-QD, respectively, were enrolled. The pharmacokinetics and CYP3A5 6986A>G and ABCB1 3435C>T pharmacogenetics of each formulation were analyzed on day 28 posttransplantation.Results. The dose-adjusted trough level (C-0) and area under the concentration-time curve (AUC(0-24)) of tacrolimus were approximately 25% lower for Tac-QD than Tac-BID. However, there was a good correlation between the AUC(0-24) and C-0 in the Tac-BID and Tac-QD groups (r(2)=0.575, P